The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?

Journal of Alzheimer's Disease : JAD
Patrick G Kehoe, Peter A Passmore

Abstract

There is an urgent need to improve upon Alzheimer's disease (AD) treatments. Limitations of existing drugs are that they target specific downstream neurochemical abnormalities while the upstream underlying pathology continues unchecked. Preferable treatments would be those that can target a number of the broad range of molecular and cellular abnormalities that occur in AD such as amyloid-β (Aβ) and hyperphosphorylated tau-mediated damage, inflammation, and mitochondrial dysfunction, as well more systemic abnormalities such as brain atrophy, impaired cerebral blood flow (CBF), and cerebrovascular disease. Recent pre-clinical, epidemiological, and a limited number of clinical investigations have shown that prevention of the signaling of the multifunctional and potent vasoconstrictor angiotensin II (Ang II) may offer broad benefits in AD. In addition to helping to ameliorate co-morbid hypertension, these drugs also likely improve diminished CBF which is common in AD and can contribute to focal Aβ pathology. These drugs, angiotensin converting enzyme (ACE) inhibitors, or angiotensin receptor antagonists (ARAs) may also help deteriorating cognitive function by preventing Ang II-mediated inhibition of acetylcholine release as well as...Continue Reading

Citations

Jun 28, 2014·PloS One·Lewis TaylorCarmen H Coxon
Dec 30, 2015·Acta Neuropathologica·Seth Love, J Scott Miners
Oct 28, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Behnam SabayanLenore J Launer
Feb 20, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hirohisa KawahataRyuichi Morishita
Nov 6, 2012·Nature Reviews. Drug Discovery·Anne CorbettClive Ballard
Jan 11, 2013·International Journal of Hypertension·Masaki MogiMasatsugu Horiuchi
Jul 25, 2019·International Journal of Epidemiology·Venexia M WalkerNeil M Davies
Sep 6, 2013·Neuropathology and Applied Neurobiology·M J C BurkeR N Kalaria
Feb 4, 2014·The Journal of Clinical Investigation·Kenneth E BernsteinMaya Koronyo-Hamaoui
Mar 7, 2014·Geriatrics & Gerontology International·Hiroyuki UmegakiNaoko Kawano
May 6, 2014·Current Hypertension Reports·Maya Koronyo-HamaouiKenneth E Bernstein
Dec 26, 2015·American Journal of Alzheimer's Disease and Other Dementias·Abhishek S ChitnisMichael L Johnson
Dec 4, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Michael A WilliamsGareth J McKay
Aug 26, 2020·Epidemiology·Venexia M WalkerPatrick G Kehoe
Aug 25, 2015·Current Hypertension Reports·Nisharahmed KheradaClive Rosendorff
Sep 18, 2020·Nature Reviews. Neurology·Clive BallardJanet Sultana
Jun 22, 2016·Brain Pathology·Seth Love, J Scott Miners
Apr 14, 2020·European Journal of Medicinal Chemistry·Thanigaimalai PillaiyarMurugesan Sankaranarayanan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.